<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.molecularpain.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Molecular Pain - Latest Articles</title>
        <link>http://www.molecularpain.com</link>
        <description>The latest research articles published by Molecular Pain</description>
        <dc:date>2012-05-09T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/8/1/36" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/8/1/35" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/8/1/34" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/8/1/33" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/8/1/32" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/8/1/31" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/8/1/30" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/8/1/29" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/8/1/28" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/8/1/27" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.molecularpain.com/content/8/1/36">
        <title>Transient receptor potential melastatin 8 (TRPM8) channels are involved in body temperature regulation</title>
        <description>Background:
Transient receptor potential cation channel subfamily M member 8 (TRPM8) is activated by cold temperature in vitro and has been demonstrated to act as a &apos;cold temperature sensor&apos; in vivo. Although it is known that agonists of this &apos;cold temperature sensor&apos;, such as menthol and icilin, cause a transient increase in body temperature (Tb), it is not known if TRPM8 plays a role in Tb regulation. Since TRPM8 has been considered as a potential target for chronic pain therapeutics, we have investigated the role of TRPM8 in Tb regulation.
Results:
We characterized five chemically distinct compounds (AMG0635, AMG2850, AMG8788, AMG9678, and Compound 496) as potent and selective antagonists of TRPM8 and tested their effects on Tb in rats and mice implanted with radiotelemetry probes. All five antagonists used in the study caused a transient decrease in Tb (maximum decrease of 0.98degreesC). Since thermoregulation is a homeostatic process that maintains Tb about 37degreesC, we further evaluated whether repeated administration of an antagonist attenuated the decrease in Tb. Indeed, repeated daily administration of AMG9678 for four consecutive days showed a reduction in the magnitude of the Tb decrease Day 2 onwards.
Conclusions:
The data reported here demonstrate that TRPM8 channels play a role in Tb regulation. Further, a reduction of magnitude in Tb decrease after repeated dosing of an antagonist suggests that TRPM8&apos;s role in Tb maintenance may not pose an issue for developing TRPM8 antagonists as therapeutics.</description>
        <link>http://www.molecularpain.com/content/8/1/36</link>
                <dc:creator>Narender Gavva</dc:creator>
                <dc:creator>Carl Davis</dc:creator>
                <dc:creator>Sonya Lehto</dc:creator>
                <dc:creator>Sara Rao</dc:creator>
                <dc:creator>Weiya Wang</dc:creator>
                <dc:creator>Dawn Zhu</dc:creator>
                <dc:source>Molecular Pain 2012, null:36</dc:source>
        <dc:date>2012-05-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-8-36</dc:identifier>
                                <prism:require>/content/figures/1744-8069-8-36-toc.gif</prism:require>
                <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>36</prism:startingPage>
        <prism:publicationDate>2012-05-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/8/1/35">
        <title>Lamina I NK1 expressing projection neurones are functional in early postnatal rats and contribute to the setting up of adult mechanical sensory thresholds.</title>
        <description>Background:
A small proportion of lamina I neurons of the spinal cord project upon the hindbrain and are thought to engage descending pathways that modulate the behavioural response to peripheral injury.  Early postnatal development of nociception in rats is associated with exaggerated and diffuse cutaneous reflexes with a gradual refinement of responses over the first postnatal weeks related to increased participation of inhibitory networks.  This study examined the postnatal development of lamina I projection neurons from postnatal day 3 (P3) until P48.
Results:
At P3, a subset of lamina I neurons were found to express the neurokinin 1 (NK1) receptor. Using fluorogold retrograde tracing, we found that the NK1 positive neurons projected upon the parabrachial nucleus (PB) within the hindbrain.  Using c-fos immunohistochemistry, we showed that lamina I and PB neurons in P3 rats responded to noxious stimulation of the periphery.  Finally, ablation of lamina I neurons with substance-P saporin conjugates at P3 resulted in increased mechanical sensitivity from P45 onwards compared to control animals of the same age.
Conclusions:
These results suggest that the lamina I pathway is present and functional at least from P3 and required for establishing and fine-tuning mechanical sensitivity in adult rats.</description>
        <link>http://www.molecularpain.com/content/8/1/35</link>
                <dc:creator>Sharon Man</dc:creator>
                <dc:creator>Sandrine Geranton</dc:creator>
                <dc:creator>Stephen Hunt</dc:creator>
                <dc:source>Molecular Pain 2012, null:35</dc:source>
        <dc:date>2012-04-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-8-35</dc:identifier>
                                <prism:require>/content/figures/1744-8069-8-35-toc.gif</prism:require>
                <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>35</prism:startingPage>
        <prism:publicationDate>2012-04-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/8/1/34">
        <title>Mitogen activated protein kinase phosphatase-1 prevents the development of tactile sensitivity in a rodent model of neuropathic pain</title>
        <description>Background:
Neuropathic pain due to nerve injury is one of the most difficult types of pain to treat. Following peripheral nerve injury, neuronal and glial plastic changes contribute to central sensitization and perpetuation of mechanical hypersensitivity in rodents. The mitogen activated protein kinase (MAPK) family is pivotal in this spinal cord plasticity. MAPK phosphatases (MKPs) limit inflammatory processes by dephosphorylating MAPKs. For example, MKP-1 preferentially dephosphorylates p-p38. Since spinal p-p38 is pivotal for the development of chronic hypersensitivity in rodent models of pain, and p-p38 inhibitors have shown clinical potential in acute and chronic pain patients, we hypothesize that induction of spinal MKP-1 will prevent the development of peripheral nerve-injury-induced hypersensitivity and p-p38 overexpression. Results: We cloned rat spinal cord MKP-1 and optimize MKP-1 cDNA in vitro using transfections to BV-2 cells. We observed that in vitro overexpression of MKP-1 blocked lipopolysaccharide-induced phosphorylation of p38 (and other MAPKs) as well as release of pro-algesic effectors (i.e., cytokines, chemokines, nitric oxide). Using this cDNA MKP-1 and a non-viral, in vivo nanoparticle transfection approach, we found that spinal cord overexpression of MKP-1 prevented development of peripheral nerve-injury-induced tactile hypersensitivity and reduced pro-inflammatory cytokines and chemokines and the phosphorylated form of p38. Conclusions: Our results indicate that MKP-1, the natural regulator of p-p38, mediates resolution of the spinal cord pro-inflammatory milieu induced by peripheral nerve injury, resulting in prevention of chronic mechanical hypersensitivity. We propose that MKP-1 is a potential therapeutic target for pain treatment or prevention.</description>
        <link>http://www.molecularpain.com/content/8/1/34</link>
                <dc:creator>Christian Ndong</dc:creator>
                <dc:creator>Russell Landry</dc:creator>
                <dc:creator>Joyce DeLeo</dc:creator>
                <dc:creator>E. Alfonso Romero-Sandoval</dc:creator>
                <dc:source>Molecular Pain 2012, null:34</dc:source>
        <dc:date>2012-04-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-8-34</dc:identifier>
                                <prism:require>/content/figures/1744-8069-8-34-toc.gif</prism:require>
                <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>34</prism:startingPage>
        <prism:publicationDate>2012-04-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/8/1/33">
        <title>Network dynamics in nociceptive pathways assessed by the neuronal avalanche model</title>
        <description>Background:
Traditional electroencephalography provides a critical assessment of pain responses. The perception of pain, however, may involve a series of signal transmission pathways in higher cortical function. Recent studies have shown that a mathematical method, the neuronal avalanche model, may be applied to evaluate higher-order network dynamics. The neuronal avalanche is a cascade of neuronal activity, the size distribution of which can be approximated by a power law relationship manifested by the slope of a straight line (i.e., the alpha value). We investigated whether the neuronal avalanche could be a useful index for nociceptive assessment.FindingsNeuronal activities were recorded with 4 X 8 multichannel electrode arrays in the primary somatosensory cortex (S1) and anterior cingulate cortex (ACC). Under light anesthesia, peripheral pinch stimulation increased the slope of the alpha value in both the ACC and S1, whereas brush stimulation increased the alpha value only in the S1. The increase in alpha values was blocked in both regions under deep anesthesia. The increase in alpha values in the ACC induced by peripheral pinch stimulation was blocked by medial thalamic lesion, but the increase in alpha values in the S1 induced by brush and pinch stimulation was not affected.
Conclusions:
The neuronal avalanche model shows a critical state in the cortical network for noxious-related signal processing. The alpha value may provide an index of brain network activity that distinguishes the responses to somatic stimuli from the control state. These network dynamics may be valuable for the evaluation of acute nociceptive processes and may be applied to chronic pathological pain conditions.</description>
        <link>http://www.molecularpain.com/content/8/1/33</link>
                <dc:creator>José Jiun-Shian Wu</dc:creator>
                <dc:creator>Hsi-Chien Shih</dc:creator>
                <dc:creator>Chen-Tung Yen</dc:creator>
                <dc:creator>Bai-Chuang Shyu</dc:creator>
                <dc:source>Molecular Pain 2012, null:33</dc:source>
        <dc:date>2012-04-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-8-33</dc:identifier>
                                <prism:require>/content/figures/1744-8069-8-33-toc.gif</prism:require>
                <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>33</prism:startingPage>
        <prism:publicationDate>2012-04-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/8/1/32">
        <title>Patients With Fibromyalgia Display Less Functional Connectivity In The Brain&apos;s Pain Inhibitory Network</title>
        <description>Background:
There is evidence for augmented processing of pain and impaired endogenous pain inhibition in Fibromyalgia syndrome (FM). In order to fully understand the mechanisms involved in FM pathology, there is a need for closer investigation of endogenous pain modulation. In the present study, we compared the functional connectivity of the descending pain inhibitory network in age-matched FM patients and healthy controls (HC).We performed functional magnetic resonance imaging (fMRI) in 42 subjects; 14 healthy and 28 age-matched FM patients (2 patients per HC), during randomly presented, subjectively calibrated pressure pain stimuli. A seed-based functional connectivity analysis of brain activity was performed. The seed coordinates were based on the findings from our previous study, comparing the fMRI signal during calibrated pressure pain in FM and HC: the rostral anterior cingulate cortex (rACC) and thalamus.
Results:
FM patients required significantly less pressure (kPa) to reach calibrated pain at 50 mm on a 0-100 visual analogue scale (p&lt;.001, two-tailed). During fMRI scanning, the rACC displayed significantly higher connectivity to the amygdala, hippocampus, and brainstem in healthy controls, compared to FM patients. There were no regions where FM patients showed higher rACC connectivity. Thalamus showed significantly higher connectivity to the orbitofrontal cortex in healthy controls but no regions showed higher thalamic connectivity in FM patients.
Conclusion:
Patients with FM displayed less connectivity within the brain&apos;s pain inhibitory network during calibrated pressure pain, compared to healthy controls. The present study provides brain-imaging evidence on how brain regions involved in homeostatic control of pain are less connected in FM patients. It is possible that the dysfunction of the descending pain modulatory network plays an important role in maintenance of FM pain and our results may translate into clinical implications by using the functional connectivity of the pain modulatory network as an objective measure of pain dysregulation.</description>
        <link>http://www.molecularpain.com/content/8/1/32</link>
                <dc:creator>Karin Jensen</dc:creator>
                <dc:creator>Rita Loitoile</dc:creator>
                <dc:creator>Eva Kosek</dc:creator>
                <dc:creator>Frank Petzke</dc:creator>
                <dc:creator>Serena Carville</dc:creator>
                <dc:creator>peter Fransson</dc:creator>
                <dc:creator>Hanke Marcus</dc:creator>
                <dc:creator>Steven Williams</dc:creator>
                <dc:creator>Ernest Choy</dc:creator>
                <dc:creator>Yves Mainguy</dc:creator>
                <dc:creator>Olivier Vitton</dc:creator>
                <dc:creator>Richard Gracely</dc:creator>
                <dc:creator>Randy Gollub</dc:creator>
                <dc:creator>Martin Ingvar</dc:creator>
                <dc:creator>Jian Kong</dc:creator>
                <dc:source>Molecular Pain 2012, null:32</dc:source>
        <dc:date>2012-04-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-8-32</dc:identifier>
                                <prism:require>/content/figures/1744-8069-8-32-toc.gif</prism:require>
                <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>32</prism:startingPage>
        <prism:publicationDate>2012-04-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/8/1/31">
        <title>Distinct degree of radiculopathy at different levels of peripheral nerve injury</title>
        <description>Background:
Lumbar radiculopathy is a common clinical problem, characterized by dorsal root ganglion [DRG] injury and neural hyperactivity causing intense radiculopathy. However, the mechanisms involved in DRG injury have not been fully elucidated. Furthermore, little is known about the degree of radiculopathy at the various levels of nerve injury. The purpose of this study is to compare the degree of radiculopathy injury at the DRG and radiculopathy injury proximal or distal to the DRG.
Results:
The lumbar radiculopathy rat model was created by ligating the L5 nerve root 2 mm proximal to the DRG or 2 mm distal to the DRG with 6.0 silk. We examined the degree of the radiculopathy using different points of mechanical sensitivity, immunohistochemistry and in vivo patch-clamp recordings, 7 days after surgery. The rats injured distal to the DRG were more sensitive than those rats injured proximal to the DRG in the behavioral study. The number of activated microglia in laminas I-II of the L5 segmental level was significantly increased in rats injured distal to the DRG when compared with rats injured proximal to the DRG. The amplitudes and frequencies of EPSC in the rats injured distal to the DRG were higher than those injured proximal to the DRG. The results indicated that there is a different degree of radiculopathy at the distal level of nerve injury.
Conclusions:
Our study examined the degree of radiculopathy at different levels of nerve injury. Severe radiculopathy occurred in rats injured distal to the DRG when compared with rats injured proximal to the DRG. This finding helps to correctly diagnose a radiculopathy.</description>
        <link>http://www.molecularpain.com/content/8/1/31</link>
                <dc:creator>Noboru Takiguchi</dc:creator>
                <dc:creator>Munehito Yoshida</dc:creator>
                <dc:creator>Wataru Taniguchi</dc:creator>
                <dc:creator>Hiroshi Hashizume</dc:creator>
                <dc:creator>Hiroshi Yamada</dc:creator>
                <dc:creator>Nobuyuki Miyazaki</dc:creator>
                <dc:creator>Naoko Nishio</dc:creator>
                <dc:creator>Terumasa Nakatsuka</dc:creator>
                <dc:source>Molecular Pain 2012, null:31</dc:source>
        <dc:date>2012-04-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-8-31</dc:identifier>
                                <prism:require>/content/figures/1744-8069-8-31-toc.gif</prism:require>
                <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>31</prism:startingPage>
        <prism:publicationDate>2012-04-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/8/1/30">
        <title>The emergence of adolescent onset pain hypersensitivity following neonatal nerve injury.</title>
        <description>Background:
Peripheral nerve injuries can trigger neuropathic pain in adults but cause little or no pain when they are sustained in infancy or early childhood.  This is confirmed in rodent models where neonatal nerve injury causes no pain behaviour.  However, delayed pain can arise in man some considerable time after nerve damage and to examine this we have carried out a longer term follow up of rat pain behaviour into adolescence and adulthood, following early life nerve injury.
Results:
Spared nerve injury (SNI) or sham surgery was performed on 10 day old (P10) rat pups and mechanical nociceptive reflex thresholds were measured 3, 7, 14, 21, 28, 38 and 44 days post surgery. While mechanical thresholds on the ipsilateral side are not significantly different from controls for the first 2-3 weeks post P10 surgery, after that time, beginning at 21 days post surgery (P31), the SNI group developed significant hypersensitivity compared to the other groups.  Ipsilateral mechanical nociceptive thresholds were 2-fold lower than the contralateral and sham thresholds, 21 days post surgery (SNI-ipsilateral 28 (+/-5) g control groups 69 (+/-9) g, p&lt;0.001, 3-way ANOVA, n=6 per group).  Importantly, no effect was observed on thermal thresholds. This hypersensivity was accompanied by macrophage, microglial and astrocyte activation in the DRG and dorsal horn, but no significant change in dorsal horn p38 or JNK expression.  Preemptive minocycline (daily 40mg/kg, s.c) did not prevent the effect. Ketamine (1-20mg/kg, s.c), on the other hand, produced a dose-dependent reversal of mechanical nociceptive thresholds ipsilateral to the nerve injury and thresholds returned to control levels at the highest doses.
Conclusions:
We report a novel consequence of early life nerve injury whereby mechanical hypersensitivity only emerges later in life. This delayed adolescent onset in mechanical pain thresholds is accompanied by neuroimmune activation and NMDA dependent central sensitization of spinal nociceptive circuits. This delayed onset in mechanical pain sensitivity may provide clues to understanding the long term effects of early injury such as late onset phantom pain and the emergence of complex adolescent chronic pain syndromes.</description>
        <link>http://www.molecularpain.com/content/8/1/30</link>
                <dc:creator>David Vega-Avelaira</dc:creator>
                <dc:creator>Rebecca McKelvey</dc:creator>
                <dc:creator>Gareth Hathway</dc:creator>
                <dc:creator>Maria Fitzgerald</dc:creator>
                <dc:source>Molecular Pain 2012, null:30</dc:source>
        <dc:date>2012-04-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-8-30</dc:identifier>
                                <prism:require>/content/figures/1744-8069-8-30-toc.gif</prism:require>
                <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>30</prism:startingPage>
        <prism:publicationDate>2012-04-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/8/1/29">
        <title>Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study</title>
        <description>The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients. Our lab has reported that this treatment reduces CBP intensity and associated brain activations when tested in an open labelled preliminary study.  Notably, effectiveness of the 5% Lidocaine patch has not been tested against placebo for treating CBP. In this study, effectiveness of the 5% Lidocaine patch was compared with placebo in 30 CBP patients in a randomised double-blind study where 15 patients received 5% Lidocaine patches and the remaining patients received placebo patches. Functional MRI was used to identify brain activity for fluctuations of spontaneous pain, at baseline and at two time points after start of treatment (6 hours and 2 weeks). There was no significant difference between the treatment groups in either pain intensity, sensory and affective qualities of pain or in pain related brain activation at any time point. However, 50% patients in both the Lidocaine and placebo arms reported a greater than 50% decrease in pain suggesting a marked placebo effect. When tested against an untreated CBP group at similar time points, the patch treated subjects showed significantly greater decrease in pain compared to the untreated group (n=15). These findings suggest that although the 5% Lidocaine is not better than placebo in its effectiveness for treating pain, the patch itself induces a potent placebo effect in a significant proportion of CBP patients.</description>
        <link>http://www.molecularpain.com/content/8/1/29</link>
                <dc:creator>Javeria Hashmi</dc:creator>
                <dc:creator>Marwan Baliki</dc:creator>
                <dc:creator>Mona Chanda</dc:creator>
                <dc:creator>Lejian Huang</dc:creator>
                <dc:creator>Elle Parks</dc:creator>
                <dc:creator>Thomas Schnitzer</dc:creator>
                <dc:creator>Vania Apkarian</dc:creator>
                <dc:source>Molecular Pain 2012, null:29</dc:source>
        <dc:date>2012-04-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-8-29</dc:identifier>
                                <prism:require>/content/figures/1744-8069-8-29-toc.gif</prism:require>
                <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>29</prism:startingPage>
        <prism:publicationDate>2012-04-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/8/1/28">
        <title>PAPupuncture has localized and long-lasting antinociceptive effects in mouse models of acute and chronic pain</title>
        <description>Acupuncture has been used for millennia to treat pain, although its efficacy and duration of action is limited.  Acupuncture also has brief (1-2 h) antinociceptive effects in mice and these effects are dependent on localized adenosine A1 receptor (A1R) activation.  Intriguingly, adenosine 5&apos;-monophosphate (AMP) is basally elevated near acupuncture points.  This finding suggested that it might be possible to inhibit nociception for a longer period of time by injecting prostatic acid phosphatase (PAP, ACPP) into acupuncture points.  PAP is an ectonucleotidase that dephosphorylates extracellular AMP to adenosine, has a long-half life in vivo and is endogenously found in muscle tissue surrounding acupuncture points.  Here, we found that injection of PAP into the popliteal fossa--a space behind the knee that encompasses the Weizhong acupuncture point--had dose- and A1R-dependent antinociceptive effects in mouse models of acute and chronic pain.  These inhibitory effects lasted up to six days following a single injection, much longer than the hour-long inhibition provided by acupuncture.  Antinociception could be transiently boosted with additional substrate (AMP) or transiently blocked with an A1R antagonist or an inhibitor of phospholipase C.  This novel therapeutic approach--which we term &quot;PAPupuncture&quot;--locally inhibits pain for an extended period of time (100x acupuncture), exploits a molecular mechanism that is common to acupuncture, yet does not require acupuncture needle stimulation.</description>
        <link>http://www.molecularpain.com/content/8/1/28</link>
                <dc:creator>Julie Hurt</dc:creator>
                <dc:creator>Mark Zylka</dc:creator>
                <dc:source>Molecular Pain 2012, null:28</dc:source>
        <dc:date>2012-04-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-8-28</dc:identifier>
                            <dc:title>PAPupuncture as a long-lasting pain relief treatment</dc:title>
                            <dc:description>Injecting prostastic acid phosphatise (PAP) into acupuncture points has antinociceptive effects in mouse models of acute and chronic pain, these effects last 100 times longer than a traditional acupuncture treatment.</dc:description>
                <prism:require>/content/figures/1744-8069-8-28-toc.gif</prism:require>
                <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>28</prism:startingPage>
        <prism:publicationDate>2012-04-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/8/1/27">
        <title>The effect of minocycline on the masticatory movements following the inferior alveolar nerve transection in freely moving rats </title>
        <description>Background:
To determine the effects of inferior alveolar nerve transection (IAN-X) on masticatory movements in freely moving rats and to test if microglial cells in the trigeminal principal sensory nucleus (prV) or motor nucleus (motV) may be involved in modulation of mastication, the effects of microglial cell inhibitor minocycline (MC) on masticatory jaw movements, microglia (Iba1) immunohistochemistry and the masticatory jaw movements and related masticatory muscle EMG activities were studied in IAN-X rats.
Results:
The number of Iba1-immunoreactive (IR) cells both in prV and motV was significantly larger in IAN-X rats compared with sham rats on day 3 after IAN-X. The intraperitoneal (i.p.) administration of MC caused a significant reduction of the number of Iba1-IR cells both in prV and motV that was evident on day 14 after IAN-X. Furthermore, a significant reduction of the number of Iba1-IR cells could be observed in motV but not in prV after microinjection (m.i.) of MC into the motV of IAN-X rats. The rats also exhibited a significant decrease in the head-withdrawal threshold on the side ipsilateral to the IAN-X compared to the threshold before IAN-X and it lasted to day 14. In addition, IAN-X markedly affected the ability to rat to carry out mastication. The number of complete masticatory sequences was significantly decreased. Furthermore, the total masticatory sequence time and food preparatory (PP) period duration was significantly elongated in compared to sham rats. Although IAN-X significantly affected the total number of chewing cycles within the RC period of a masticatory sequence, it had no effect on the duration of the chewing cycles. On the other hand, systemic administration of MC (both i.p. and m.i.) in IAN-X rats significantly improved decreased head-withdrawal threshold and the impaired masticatory jaw movements.
Conclusions:
The present findings reveal that the strong modulation of masticatory jaw movements occurs following microglial cell activation after IAN-X, and the modulation recovers after inhibition of the microglial cell activation by MC, suggesting that microglial cell activation in the motV as well as in the prV has a pivotal role in modulating mastication following trigeminal nerve injury associated with orofacial neuropathic pain.</description>
        <link>http://www.molecularpain.com/content/8/1/27</link>
                <dc:creator>Rahman Mostafeezur</dc:creator>
                <dc:creator>Hossain Zakir</dc:creator>
                <dc:creator>Yoshiaki Yamada</dc:creator>
                <dc:creator>Kensuke Yamamura</dc:creator>
                <dc:creator>Koichi Iwata</dc:creator>
                <dc:creator>Barry Sessle</dc:creator>
                <dc:creator>Junichi Kitagawa</dc:creator>
                <dc:source>Molecular Pain 2012, null:27</dc:source>
        <dc:date>2012-04-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-8-27</dc:identifier>
                                <prism:require>/content/figures/1744-8069-8-27-toc.gif</prism:require>
                <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>27</prism:startingPage>
        <prism:publicationDate>2012-04-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

